NeoGenomics Prices the Convert, Not the Cleanup

Scope note: this run is explicitly limited to U.S. market focus and long only. Before selection, I scanned the current articles/2026-06/week-3/ folder, repo-wide titles and slugs, and the mispricing-us-market automation memory. Current-week U.S.-long topics already covered or reserved include UNCY, OLN, and PTRN; the local folder also contains non-U.S. or other-scope drafts. I did not find a prior NeoGenomics common-stock article. Creative search lanes used for this run: "convertible-arbitrage hedge unwind where the financing cleans the old paper," "capped call makes dilution the wrong headline," "diagnostics stock refinancing old convert while revenue guidance improves," and "notes offering where buyers may have to buy stock, not just short it."

Summary: NeoGenomics (NEO) traded at $10.595 at 2026-06-17 19:07:45 UTC in Yahoo Finance's live chart feed, after the stock fell from $11.47 on June 11 to $10.49 on June 16 around a new convertible-note package.[1] The headline looks dilutive. The filing reads more like capital-structure cleanup: a $275 million 0.75% convertible due 2032, a $20.98 capped-call cap equal to 100% of the June 16 close, repurchase of $276 million principal amount of 0.25% converts due 2028 for about $263.19 million, and a possible $25 million common-stock repurchase from note purchasers.[2] The closing catalyst is dated: the offering is expected to close on June 22, 2026, subject to customary conditions.[2]

This is not a clean "convert bad, stock good" article. The strongest counterargument is that NeoGenomics remains loss-making and is replacing one convert with a larger, longer-dated convert. The mispricing is narrower: the market appears to be pricing the financing as fresh dilution while underweighting three offsetting mechanics: discounted retirement of old paper, capped-call protection to a double, and short-term hedge or buyback flows that can force the stock back toward the pre-announcement range.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	Long `NEO` common	U.S. diagnostics / convertible cleanup / hedge-flow reversal	The tape sold the 2032 convert headline even though the package retires $276 million of 2028 notes for about $263.19 million, funds capped calls up to $20.98, and may repurchase $25 million of stock from note purchasers.[2]	High: June 17 pricing release, June 17 live chart feed, April 28 Q1 release and 10-Q.	June 22 expected offering close, then confirmation of note retirement, share repurchase execution, and Q2 operating follow-through.	From $10.595, a return to $11.13 is +5.0%. That is still below the June 11 close of $11.47 and below the June 10 intraday high of $11.82.[1]	The bottom case is a financing hangover, but the top case gets capital-structure relief plus hedge-flow support without needing a heroic operating rerate.	Selected. Main risk is that the market is correctly requiring a lower equity value for a still-loss-making diagnostics company.
2	Long `ADPT` common	U.S. biotech tools / royalty-debt payoff / business separation	Adaptive priced $300 million of 0% converts due 2031, plans to repay a burdensome OrbiMed revenue-interest agreement at a $156.9 million payoff, funds capped calls with a $34.44 cap, and repurchases 1,451,800 shares.[3][4]	High: June 17 pricing and June 15 SEC statement.	June 22 expected settlement and year-end 2026 preferred separation path.	From $16.69, +5% is $17.52, only slightly above the June 16 close of $17.22 and below the June 11 close of $18.73.[1]	Stronger strategic optionality than `NEO`, but the stock did not dislocate as cleanly and the business separation adds execution ambiguity.	Rejected because the thesis blends financing cleanup with a larger strategic separation, making the near-term price gap less clean.
3	Long `IIPR` common	U.S. REIT / exchangeable-note financing / cannabis credit	IIPR issued $402.5 million of 6.00% exchangeable notes due 2029, repurchased 1,334,466 shares at $60.34, and set the exchange price near $69.39.[5]	High: June 15 8-K and June 17 quote.	Offering already closed June 15; next catalysts are debt deployment and tenant-credit evidence.	From $58.90, +5% is $61.85, close to the June 11 high of $61.77.[1]	Real upside if the market reclassifies the deal as maturity management, but cannabis tenant credit is a legitimate reason for the discount.	Rejected because the fundamental counterargument is more obvious and the catalyst is less immediate after the deal already closed.

Selected opportunity: Long NEO common stock.

Why this one now: NEO has the cleanest live disagreement between headline dilution and transaction mechanics. The package extends maturity, pays for capped-call protection, retires old paper at a discount to principal, and may add a same-transaction stock repurchase.[2]

Why it can jump more than 5% soon: A move from $10.595 to $11.13 clears +5.0%. That level is below where the stock traded on June 10 and June 11, before the financing became the tape's main object.[1] The June 22 expected close is a hard near-term checkpoint.[2]

What should surprise the reader: The most important flow may not be note buyers shorting stock. The company's own release says capped-call counterparties and hedged holders of existing notes may buy NeoGenomics stock or unwind derivatives around pricing and note repurchase activity.[6]

The Setup

NeoGenomics is not issuing common stock into a vacuum. It is refinancing the capital stack while the operating business is improving from a weak base.

First-quarter revenue rose 11% year over year to $187 million, a first-quarter record according to the company. Net loss narrowed 34% to $17 million, and adjusted EBITDA increased 27% to $9.0 million.[7] The 10-Q shows net revenue of $186.7 million, net loss of $17.1 million, and cash and equivalents of $146.1 million at March 31, 2026.[8]

Then came the financing. On June 17, NeoGenomics priced $275 million of 0.75% convertible senior notes due 2032, with an initial purchaser option for another $41.25 million. Estimated net proceeds are $266.15 million, or $306.16 million if the option is fully exercised.[2]

The market appears to have read "convertible" first and "cleanup" second. The stock closed at $11.47 on June 11, $11.15 on June 12, $11.09 on June 15, and $10.49 on June 16. It traded at $10.595 at 19:07:45 UTC on June 17 on volume already above 11.8 million shares, far above the prior week's daily volume.[1]

The Mispricing

The error is not that dilution is impossible. Dilution is explicitly possible above the conversion price, and the capped call only protects up to its cap. The error is treating the deal as if it were ordinary equity leakage rather than a multi-leg refinancing.

The pricing release says the capped-call cap will initially be $20.98 per share, a 100% premium to the June 16 last reported sale price of $10.49.[2] It also says NeoGenomics intends to use proceeds, together with cash on hand, to repurchase $276 million principal amount of its 0.25% convertible senior notes due 2028 for about $263.19 million.[2]

That is the core disagreement:

Fact: The new convert is larger and longer dated.
Fact: The old convert is being retired below principal value.
Fact: The capped call reduces dilution or cash-payment exposure up to a defined cap.
Fact: The company may repurchase up to $25 million of common stock from certain note purchasers.
Inference: A stock trading near $10.60 does not need the market to love diagnostics. It only needs the market to stop treating the whole package as unprotected dilution.

Price

Market Level	Value	Timestamp	Source	Use
`NEO` live chart price	$10.595	2026-06-17 19:07:45 UTC	Yahoo Finance chart API [1]	Current entry reference.
June 16 close	$10.49	2026-06-16 regular session	Yahoo Finance chart API and company pricing release [1][2]	Conversion and capped-call premium reference.
June 11 close	$11.47	2026-06-11 regular session	Yahoo Finance chart API [1]	Pre-financing reference.
June 10 intraday high	$11.82	2026-06-10 regular session	Yahoo Finance chart API [1]	Near-term rebound reference.
New notes	$275 million, 0.75%, due 2032	Announced June 17, 2026	NeoGenomics pricing release [2]	Financing headline.
Capped-call cap	$20.98	Announced June 17, 2026	NeoGenomics pricing release [2]	Dilution protection level.
Existing-note repurchase	$276 million principal for about $263.19 million	Announced June 17, 2026	NeoGenomics pricing release [2]	Cleanup mechanic.

The simple near-term price test is not ambitious. A move back to $11.13 is +5.0% from the live reference. A return to the June 11 close is about +8.3%. A return to the June 10 high is about +11.6%.[1]

Positioning

The best positioning evidence is not perfect, but it is usable.

Short interest was already material before the financing. MarketBeat reports 8,486,518 shares sold short as of May 29, 2026, equal to 6.59% of the public float and 6.9 days to cover at its stated average volume.[9] StockAnalysis reports a similar latest short-interest figure of 8.62 million shares, 7.30% of float, and a 3.41 short ratio, reflecting a different data snapshot or average-volume convention.[10]

More important, the financing itself can create two-way flow. NeoGenomics says option counterparties establishing capped-call hedges may purchase shares or derivatives around pricing, and hedged holders of the old notes who agree to repurchase transactions may unwind hedges by buying common stock or related derivatives.[6] This does not guarantee support. It does mean "new convert equals automatic stock short" is too crude.

Missing-data note: I do not have live prime-broker borrow cost, dealer gamma, real-time convert-arb short inventory, or executed share-repurchase confirmation. The article therefore treats hedge and repurchase flows as documented possible mechanics, not as confirmed completed flows.

Catalyst

The first catalyst is mechanical: the offering is expected to close on June 22, 2026, subject to customary conditions.[2] A clean close matters because it should convert the announcement from uncertainty into a funded capital-structure action.

The second catalyst is confirmation of the old-note repurchase and common-stock repurchase. If the company confirms the $276 million existing-note repurchase and any meaningful portion of the $25 million stock buyback, the market has to decide whether the selloff was pricing real dilution or temporary financing indigestion.[2]

The third catalyst is operating follow-through. Q1 showed revenue growth, narrower net loss, positive adjusted EBITDA, and revised 2026 revenue guidance of $797 million to $803 million with adjusted EBITDA guidance of $55 million to $57 million.[7] The financing is easier to underwrite if Q2 confirms that Q1 was not a one-quarter margin artifact.

Payoff Map

This is a short-horizon common-stock trade, not a long-duration valuation essay. The payoff is modest but asymmetric because the required upside to validate the setup is small while the invalidation can be defined around deal close, price action, and operating evidence.

Top case: the June 22 close clears, old-note repurchase is confirmed, hedge or repurchase flows absorb the financing hangover, and the stock returns to the early-June range.
Base case: the financing closes, but investors wait for Q2 evidence before paying for the cleaner structure.
Bottom case: the market is right that the company has merely extended dilution risk while burning cash in a competitive oncology-testing market.

The probability-weighted expected value using the scenario target prices below is:

(30% * $12.50) + (45% * $11.25) + (25% * $8.75) = $11.00

Against the $10.595 live reference, that is about +3.8% expected price value before trading costs. The headline EV is not large. The trade is still publishable because the setup has a dated catalyst, a low +5% hurdle, and a clear invalidation path.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	30%	$12.50	+18.0% from $10.595	1-4 weeks	June 22 close clears, existing-note repurchase is confirmed, common-stock repurchase or hedge-unwind flows absorb supply, and investors re-anchor to the pre-financing range.	Medium
Base Case	45%	$11.25	+6.2%	1-4 weeks	Financing closes without adverse surprise, but the stock needs Q2 evidence before a larger rerate.	Medium
Bottom Case	25%	$8.75	-17.4%	1-8 weeks	Deal terms are digested as larger net debt, Q2 momentum weakens, or diagnostics multiples compress.	Medium
Invalidation / Stop Condition	n/a	Below $9.70 or adverse financing-close update	n/a	Immediate to 2 weeks	Break below the post-announcement low zone on volume, failure to close the offering, worse-than-disclosed repurchase terms, or operating update that undermines the Q1 improvement.	Medium

Probability-weighted expected value: $11.00, about +3.8% versus the live reference before costs. Current market price / level: NEO $10.595 at 2026-06-17 19:07:45 UTC.[1] Timestamp: Article drafted 2026-06-18 02:11 +07 using live market data from the June 17 U.S. session. Primary instrument: NEO common stock. Alternative expressions considered: options were rejected because I did not have reliable live chain, skew, spread, or open-interest data in this run; the new convert itself was rejected because the article is about equity mispricing and because note pricing requires a separate credit and volatility model. Confidence: Medium.

What Would Prove This Wrong

The thesis breaks if the June 22 close fails or changes materially. It also breaks if the existing-note repurchase is smaller or more expensive than disclosed, if the company does not execute any meaningful common-stock repurchase despite using it as an offsetting mechanic, or if post-close trading stays below $10.00 with no evidence of hedge-flow support.

The deeper kill shot is operating. NeoGenomics still reported a GAAP net loss of $17.1 million and used $8.1 million of operating cash in Q1.[8] If Q2 shows that revenue growth is slowing or adjusted EBITDA is not translating into cash discipline, the new structure is not a cleanup. It is more runway bought with another convertible claim.

Risk Audit

Strongest counterargument: The market may be correctly discounting a loss-making diagnostics company that has now layered on a larger 2032 convertible. The capped call softens dilution only up to a cap. It does not create value by itself.

Most fragile assumption: The old-note repurchase and possible stock repurchase are enough to make investors treat the financing as cleanup rather than dilution.

What the market may already know: Convertible investors and equity investors may already understand the capped-call math and still decide the company's operating profile does not deserve a higher multiple.

What could make the trade lose money even if the thesis is directionally right: The financing can close cleanly while the stock drifts lower because convert-arb hedging, sector weakness, or tax-loss style de-risking overwhelms the buyback and hedge-unwind support.

Liquidity / execution risks: June 17 volume was unusually high at more than 11.8 million shares by the Yahoo chart snapshot, but normal daily volume is lower. Chasing a spike can turn a defined setup into poor execution.[1]

Leverage risks: The new notes extend maturity but add a large claim due 2032. Refinancing risk is reduced near term, not eliminated.

Information reliability risks: Live borrow cost, exact option-chain pricing, and executed repurchase details were not available. The article uses company filings and public market data, not dealer-position data.

Invalidation trigger: Failure or adverse revision of the June 22 close; confirmed non-execution of expected cleanup mechanics; break below $9.70 on financing-related volume; Q2 evidence that revenue growth or EBITDA improvement is fading.

Publish / revise / reject recommendation: Publish as a medium-conviction Deep Dive Trade Note. The evidence is fresh and the closing window is near, but the EV is modest and the operating business still carries real cash-flow risk.

Bottom Line

NEO is a long because the market is pricing the June financing as a dilution event while the documents describe a capital-structure cleanup with capped-call protection, old-note retirement, possible stock repurchase, and near-term hedge-flow asymmetry. The trade does not need a heroic oncology-testing rerate. It needs the June 22 close to confirm that the financing was less toxic than the first tape reaction implied.

Best Trade Strategy

Direction: Long.

Preferred instrument: NEO common stock.

Common-stock stance: Buy only near the financing-dislocation zone, not after a large gap. The cleanest expression is common stock because the thesis depends on near-term equity re-anchoring and possible stock/hedge-flow support.

Options stance: No options trade selected. I did not have reliable live option-chain, implied-volatility, skew, spread, or open-interest data. Using calls without that data would be fake precision.

Take-profit map: First target $11.25. Stretch target $12.50 if the June 22 close confirms the cleanup and the stock reclaims the early-June range.

Stop loss / invalidation: Price break below $9.70 on financing-related volume, failed or adverse offering close, worse old-note repurchase economics than disclosed, or Q2 evidence that Q1 improvement is fading.

Timeline: 1-4 weeks for the financing-close and flow-normalization thesis. 1-8 weeks if the trade requires Q2 operating confirmation.

Execution risks: High post-announcement volume can mean better liquidity or a crowded arb tape. Use limit orders. Do not buy if the stock gaps straight through the base target before the June 22 close.

Do-not-trade conditions: Do not trade if June 22 close news is adverse, if the stock is already above $12.50 before confirmation, if borrow or option data reveals a much more crowded hedge book than public data suggests, or if a new company filing changes use-of-proceeds economics.

Monitoring checklist:

June 22 offering close status.
Confirmation of $276 million existing-note repurchase and final cost.
Confirmation or evidence of any $25 million common-stock repurchase.
Price behavior around $11.13, $11.25, and $12.50.
Q2 revenue, adjusted EBITDA, operating cash flow, and updated 2026 guidance.
Short-interest update after the financing and any abnormal borrow-cost change.

Research Quality Scorecard

Criterion	Score	Rationale
Market disagreement	5	Clear disagreement between headline convert dilution and the documented cleanup mechanics.
Evidence base	5	Core facts come from June 17 company pricing release, April Q1 release, 10-Q, and live Yahoo chart data.
Positioning and flows	4	Short interest and documented hedge-flow mechanics are useful, but live borrow and dealer data are missing.
Catalyst path	5	June 22 expected close is a dated near-term catalyst.
Payoff architecture	4	Defined top/base/bottom map and EV, but the expected value is modest.
Invalidation discipline	4	Clear price, deal, and operating invalidation triggers.
Differentiated insight	4	The overlooked point is not "convert bullish"; it is discounted old-note retirement plus capped-call and hedge-flow asymmetry.
Client value	4	Useful as a financing-structure audit even if no trade is taken.

Total: 35 / 40.

Section 17 Quality Gate

Gate	Answer	Note
1. Is the mispricing specific?	yes	Specific to `NEO`'s June 2026 convert cleanup.
2. Is there evidence beyond narrative?	yes	Pricing release, Q1 release, 10-Q, chart data, short-interest sources.
3. Is the positioning claim supported or clearly labeled as uncertain?	yes	Public short data cited; missing borrow/dealer data labeled.
4. Is there a catalyst or plausible closing mechanism?	yes	June 22 expected close and repurchase confirmation path.
5. Is the downside case described honestly?	yes	Loss-making company, larger 2032 claim, weak Q2 risk.
6. Is the strongest counterargument included?	yes	Market may be correctly discounting dilution and operating losses.
7. Is the article useful even if the trade is not taken?	yes	It audits financing mechanics and flow assumptions.
8. Are all factual claims sourced or marked as unverified?	yes	Missing live borrow/options/dealer data explicitly marked.
9. Does the article avoid hype?	yes	No promotional language.
10. Does the headline match the actual evidence?	yes	The thesis is convert headline versus cleanup mechanics.
11. Does the article explain why this is the best opportunity right now?	yes	Ranking compares `NEO`, `ADPT`, and `IIPR`.
12. Does it explain why the asset can plausibly move more than 5% soon?	yes	+5% level, trigger, timeframe, and evidence quality included.
13. Does it identify what should surprise a sophisticated reader?	yes	Hedge-flow and old-note cleanup mechanics.
14. Does it include top, base, and bottom targets with probabilities adding to 100%?	yes	30% + 45% + 25% = 100%.
15. Does the main article include its Research Quality Scorecard?	yes	Dedicated section included.
16. Are reader-facing tables Markdown tables?	yes	All tables are Markdown.
17. If optional table images were requested, are they separate?	n/a	No table images requested.
18. If an illustration prompt was required, is it inline with watermark requirement?	yes	Included below.
19. Does it include Best Trade Strategy with required fields?	yes	Direction, instrument, common, options, TP, SL, timeline, risks, do-not-trade, monitoring, sourced price.
20. If technical signals are used, are they only timing inputs?	n/a	The thesis does not rely on technical signals.
21. Unless unscoped, did it screen U.S., Japan, broader Asia, and Europe / UK?	n/a	User explicitly scoped this run to U.S. market long only.
22. If Japan was used, did it follow Japan small/mid and <= JPY 800 discipline?	n/a	Japan was outside explicit scope.
23. If live Substack finish was requested, was it actually created or updated?	n/a	No Substack finish requested.

Sources

Ref	Source	Used For
[1]	Yahoo Finance chart API for `NEO`, `ADPT`, `IIPR`, and `SPY`, queried 2026-06-18 02:00-02:10 +07	Live and recent daily prices, timestamps, and volume.
[2]	NeoGenomics pricing release, June 17, 2026	New note size, coupon, maturity, June 22 expected close, capped-call cap, use of proceeds, old-note repurchase, possible stock repurchase.
[3]	Adaptive Biotechnologies proposed notes 8-K, June 15, 2026	Candidate screen facts for `ADPT` proposed notes and business separation announcement.
[4]	Adaptive Biotechnologies SEC statement on OrbiMed repayment, June 15, 2026 and pricing-release excerpt from StockTitan	OrbiMed payoff amount, 0% convert pricing, cap, and stock repurchase details for rejected candidate.
[5]	Innovative Industrial Properties 8-K, June 15, 2026	IIPR exchangeable-note terms, share repurchase amount and price.
[6]	NeoGenomics proposed offering release, June 15, 2026	Capped-call and old-note hedge-flow mechanics.
[7]	NeoGenomics Q1 2026 results release, April 28, 2026	Q1 revenue growth, net loss improvement, adjusted EBITDA, 2026 guidance.
[8]	NeoGenomics 10-Q for quarter ended March 31, 2026	Revenue, net loss, cash, operating cash flow, balance-sheet data.
[9]	MarketBeat NeoGenomics short interest	May 29 short interest, short percent of float, and days to cover.
[10]	StockAnalysis NeoGenomics statistics	Cross-check of latest short-interest and float percentages.

Illustration Prompt

Create a realistic, high-value, high-end elite, beautiful master editorial image for The Mispricing Desk about NeoGenomics and the market mistaking a convertible-note cleanup for plain dilution. Show a quiet institutional oncology diagnostics lab after market close, half laboratory and half capital-markets desk. In the foreground, place a precise stack of old paper labeled 2028 converts retired: $276M principal sliding into a shredder made of brushed steel, while a new clean note certificate labeled 2032 convert 0.75% sits under a transparent capped-call dome engraved $20.98 cap. Beside it, a small buyback ticket reads up to $25M common. In the background, sample racks and sequencing machines glow in cool clinical light, with a restrained ticker strip reading NEO 10.595 and a calendar tab marked June 22 close. The visual metaphor should be forensic cleanup, not speculative biotech hype. Mood: disciplined, clinical, expensive, skeptical. Palette: graphite, surgical white, deep teal, muted violet assay light, and small amber trading-screen accents. No rockets, no DNA cartoon, no generic upward arrows, no stock-photo doctors, no sensational casino imagery, no AI slop. Include a subtle but clear watermark or etched text reading The Mispricing Desk.